Perioperative SDD to Prevent Infectious Complications After Esophagectomy

Prior treatment

• Patients planned for rescue surgery,
• Patients who have undergone upper GI surgery within 30 days before randomization,

Other illness

• Patients with a known allergy, sensitivity, or interaction to investigational medicinal product.
• Patients with pre-existing degenerative neuromuscular diseases like, but not limited to, myasthenia gravis or Parkinson disease).

Lab values

• Patients with documented chronic renal failure (GFR \< 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis,

Other

• Patients planned for colonic interposition,
• Known or suspected pregnancy,
• Unable to understand the study information, study instructions and give informed consent.
• Patients enrolled in a trial that would interact with the intervention
• Patients with known/documented colonization of Enterobacteriaceae and or Pseudomonas Aeruginosa that are resistant to both tobramycin/gentamicin and to carbapenem antibiotics
• Patients undergoing CVVH.
• Women of childbearing potential at risk of pregnancy, not using adequate contraception,
• Patients with the inability to swallow the SDD

• Diagnosis of primary esophageal adenocarcinoma or squamous cell carcinoma (cT1b-4a,N0-3,M0) in the mid or distal esophagus or at the level of the gastro-esophageal junction scheduled for undergoing transthoracic esophagectomy with curative intent or for esophageal reconstruction with a gastric or jejunal interposition
• Age ≥ 18 years,
• Able to give written informed consent.